The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Would Proposed New Rule for Repricing Long-Listed Drugs Create Winners and Losers? Bill Payers Opposed, Industry Watching Closely
December 5, 2013
-
BUSINESS Ono Joins SGLT-2 Inhibitor Battle via Copromotion Deal with AstraZeneca
December 4, 2013
-
BUSINESS Reimbursement Listing of Ipragliflozin Expected in April; 4 Rival SGLT-2 Inhibitors Seen to Follow Suit 1 Month Later
December 3, 2013
-
BUSINESS Merck to Shed 200 Jobs in Japan by 2015
December 3, 2013
-
BUSINESS GSK Exec Tapped as Takeda’s Next President, 1st Non-Japanese to Lead Japan Juggernaut
December 2, 2013
-
BUSINESS AnGes MG to Resume Collategene Development for Critical Limb Ischemia Treatment: President Yamada
November 29, 2013
-
REGULATORY MHLW Proposes to “Institutionalize” New Drug Premium; Equivocal Wording Draws Fire at CSIMC
November 28, 2013
-
BUSINESS President Hasegawa of Takeda Confident About Achieving Targets in Midterm Growth Strategy; Company to Appoint CIO
November 28, 2013
-
BUSINESS Azilva Tops Physician “Mind Share” Ranking in GP, HP Markets in October: New Survey
November 27, 2013
-
BUSINESS Eisai to Take Over Marketing Rights for Gliadel from Nobelpharma
November 27, 2013
-
ACADEMIA All Clinical Studies Should Follow GCP Requirements: Ex-AZ Chairman Kato
November 26, 2013
-
BUSINESS Farmorubicin Approved for Additional Dosage and Administration for Hepatic Cancer: Pfizer Japan
November 26, 2013
-
BUSINESS AZ Aims to Maintain Presence in Oncology Field Via Partnerships until Launch of New Drugs
November 25, 2013
-
BUSINESS Takeda Deploys Cardiovascular, Diabetes Sales Reps for Comprehensive Detailing Activities for Lifestyle Diseases
November 22, 2013
-
BUSINESS Japan Diovan Sales Down 15.7% in July-September: IMS
November 22, 2013
-
REGULATORY JGA President Opposes 50% Rule for Generics, CSIMC Subcommittee Members Disagree
November 21, 2013
-
BUSINESS Japan Now Part of Global PIII Clinical Study for MLN9708: Takeda
November 21, 2013
-
BUSINESS US Pfizer Plans Simultaneous, Global Filing of Five Biosimilars, Eyes Japan Biosimilar Market Entry
November 20, 2013
-
ACADEMIA JAMS’ Draft of Revised Guidelines Ups Ante for COI Disclosures in Clinical Trials
November 19, 2013
-
REGULATORY PAFSC’s 1st Committee on Drugs to Review Astellas’s SGLT-2 Inhibitor Ipragliflozin on Nov. 29
November 19, 2013
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…